Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease - PubMed (original) (raw)
Review
Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease
K S McNaught et al. Biochem Pharmacol. 1998.
Abstract
The cause of neurodegeneration in Parkinson's disease (PD) remains unknown. However, isoquinoline derivatives structurally related to the selective dopaminergic toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its active metabolite, 1-methyl-4-phenylpyridinim (MPP+), have emerged as candidate endogenous neurotoxins causing nigral cell death in Parkinson's disease. Isoquinoline derivatives are widely distributed in the environment, being present in many plants and foodstuffs, and readily cross the blood-brain barrier. These compounds occur naturally in human brain where they are synthesized by non-enzymatic condensation of biogenic amines (e.g. catecholamines and phenylethylamine) with aldehydes, and are metabolized by cytochrome P450s and N-methyltransferases. In addition, isoquinoline derivatives are oxidized by monoamine oxidases to produce isoquinolinium cations with the concomitant generation of reactive oxygen species. Neutral and quaternary isoquinoline derivatives accumulate in dopaminergic nerve terminals via the dopamine re-uptake system, for which they have moderate to poor affinity as substrates. Several isoquinoline derivatives are selective and more potent inhibitors of NADH ubiquinone reductase (complex I) and alpha-ketoglutarate dehydrogenase activity in mitochondrial fragments than MPP+, and lipophilicity appears to be important for complex I inhibition by isoquinoline derivatives. However, compared with MPP+, isoquinoline derivatives are selective but less potent inhibitors of NADH-linked respiration in intact mitochondria, and this appears to be a consequence of their rate-limiting ability to cross mitochondrial membranes. Although both active and passive processes are involved in the accumulation of isoquinoline derivatives in mitochondria, inhibition of respiration is determined by steric rather than electrostatic properties. Compared with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or MPP+, isoquinoline derivatives show selective but relatively weak toxicity to dopamine-containing cells in culture and following systemic or intracerebral administration to experimental animals, which appears to be a consequence of poor sequestration of isoquinoline derivatives by mitochondria and by dopamine-containing neurones. In conclusion, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-like cytotoxic characteristics of isoquinoline derivatives and the endogenous/environmental presence of these compounds make it conceivable that high concentrations of and/or prolonged exposure to isoquinoline derivatives might cause neurodegeneration and Parkinson's disease in humans.
Similar articles
- Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter.
Storch A, Ott S, Hwang YI, Ortmann R, Hein A, Frenzel S, Matsubara K, Ohta S, Wolf HU, Schwarz J. Storch A, et al. Biochem Pharmacol. 2002 Mar 1;63(5):909-20. doi: 10.1016/s0006-2952(01)00922-4. Biochem Pharmacol. 2002. PMID: 11911843 - Inhibition of [3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
McNaught KS, Thull U, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Marsden CD. McNaught KS, et al. Biochem Pharmacol. 1996 Jul 12;52(1):29-34. doi: 10.1016/0006-2952(96)00133-5. Biochem Pharmacol. 1996. PMID: 8678905 - Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration.
McNaught KS, Thull U, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Marsden CD. McNaught KS, et al. Biochem Pharmacol. 1996 Jun 14;51(11):1503-11. doi: 10.1016/0006-2952(96)00091-3. Biochem Pharmacol. 1996. PMID: 8630091 - Isoquinoline neurotoxins in the brain and Parkinson's disease.
Nagatsu T. Nagatsu T. Neurosci Res. 1997 Oct;29(2):99-111. doi: 10.1016/s0168-0102(97)00083-7. Neurosci Res. 1997. PMID: 9359458 Review. - Endogenous risk factors in Parkinson's disease: dopamine and tetrahydroisoquinolines.
Antkiewicz-Michaluk L. Antkiewicz-Michaluk L. Pol J Pharmacol. 2002 Nov-Dec;54(6):567-72. Pol J Pharmacol. 2002. PMID: 12866710 Review.
Cited by
- Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson's disease.
Jenner P, Falup-Pecurariu C, Leta V, Verin M, Auffret M, Bhidayasiri R, Weiss D, Borovečki F, Jost WH. Jenner P, et al. J Neural Transm (Vienna). 2023 Nov;130(11):1337-1347. doi: 10.1007/s00702-023-02655-0. Epub 2023 May 20. J Neural Transm (Vienna). 2023. PMID: 37210460 Free PMC article. Review. - Endogenous Synthesis of Tetrahydroisoquinoline Derivatives from Dietary Factors: Neurotoxicity Assessment on a 3D Neurosphere Culture.
Aro R, Nachtergael A, Palmieri C, Ris L, Duez P. Aro R, et al. Molecules. 2022 Nov 2;27(21):7443. doi: 10.3390/molecules27217443. Molecules. 2022. PMID: 36364268 Free PMC article. - Further evidence for the association of CYP2D6*4 gene polymorphism with Parkinson's disease: a case control study.
Anwarullah, Aslam M, Badshah M, Abbasi R, Sultan A, Khan K, Ahmad N, von Engelhardt J. Anwarullah, et al. Genes Environ. 2017 Jul 1;39:18. doi: 10.1186/s41021-017-0078-8. eCollection 2017. Genes Environ. 2017. PMID: 28680508 Free PMC article. - 1-Methyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine with unexpected mechanism of action: new vistas of therapeutic application.
Antkiewicz-Michaluk L, Wąsik A, Michaluk J. Antkiewicz-Michaluk L, et al. Neurotox Res. 2014 Jan;25(1):1-12. doi: 10.1007/s12640-013-9402-7. Epub 2013 May 30. Neurotox Res. 2014. PMID: 23719903 Free PMC article. Review. - Chromosomal loci influencing the susceptibility to the parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sedelis M, Hofele K, Schwarting RK, Huston JP, Belknap JK. Sedelis M, et al. J Neurosci. 2003 Sep 10;23(23):8247-53. doi: 10.1523/JNEUROSCI.23-23-08247.2003. J Neurosci. 2003. PMID: 12967986 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical